Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Eli Lilly and Company is conducting a study titled ‘A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer’s Disease.’ The key objective is to evaluate the safety and efficacy of donanemab in individuals with preclinical Alzheimer’s Disease, aiming to enroll approximately 800 additional participants to assess a new titration regimen. This study is significant as it targets early intervention in Alzheimer’s, potentially altering disease progression.
Intervention/Treatment: The study tests donanemab, an experimental drug administered intravenously, against a placebo. Donanemab is designed to slow cognitive and functional decline in Alzheimer’s patients.
Study Design: This Phase 3 interventional study is randomized with a parallel assignment. It employs a double-blind approach, meaning both participants and investigators are unaware of who receives the drug or placebo. The primary purpose is treatment-focused.
Study Timeline: The study began on August 27, 2021. The primary completion and estimated completion dates are not specified, but the last update was submitted on June 24, 2025. These dates are crucial for tracking progress and anticipating results.
Market Implications: This study update may positively influence Eli Lilly’s stock performance and investor sentiment, given the potential breakthrough in Alzheimer’s treatment. Success in this study could position Eli Lilly favorably against competitors in the Alzheimer’s treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.